Department of Immunology, University of Connecticut School of Medicine, Farmington, USA.
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
由于侵袭性卵巢癌的生存率较低，因此迫切需要新的有效治疗方法。有令人信服的证据表明，针对卵巢癌的免疫反应可能在控制这种疾病方面发挥重要作用。我们在此总结了多种已被提出并针对晚期卵巢癌进行潜在治疗益处测试的基于免疫的策略。我们将研究一个有效的针对卵巢癌的治疗性疫苗不仅可用于诱导疾病缓解，而且还可用于预防疾病复发这一前提的证据。我们还将突出卵巢癌疫苗开发中的问题和挑战，并批判性地讨论一些现有的免疫治疗策略的局限性。最后，我们将总结我们在使用患者特异性肿瘤衍生热休克蛋白肽复合物治疗晚期卵巢癌方面的经验。
